Related Experiment Videos
Fas and Fas-ligand expression in seminomatous testes.
O Braendstrup1, B Bols, L Jensen
1Department of Pathology, Glostrup Hospital, Denmark.
Summary
Seminomas show limited Fas ligand expression on tumor cells, suggesting immune evasion. Normal tubules express Fas ligand, potentially contributing to immune privilege in the testis.
Area of Science:
- Immunology
- Oncology
- Histopathology
Background:
- Seminomas are testicular germ cell tumors.
- The testis is considered an immunologically privileged site.
- Fas (CD95, APO-1) and Fas ligand (FasL) (CD95L) are key mediators of apoptosis and immune regulation.
Purpose of the Study:
- To investigate the expression of Fas and FasL in seminomas and surrounding testicular tissue.
- To understand the role of Fas/FasL in the immune microenvironment of seminomas.
Main Methods:
- Immunohistochemistry was performed on frozen specimens of 16 seminomas and surrounding tissues.
- Antibodies against Fas and FasL were used to detect their expression.
- Analysis included tumor-infiltrating lymphocytes, normal and precancerous seminiferous tubules, and rete testis.
Main Results:
- Fas-positive lymphocytes were present in tumor infiltrates (approx. 20%), but FasL-positive lymphocytes were rare.
- Normal seminiferous tubules expressed FasL, mainly at the basal epithelium; this expression was reduced in precancerous tubules.
- Fas was not expressed in normal tubules, with occasional positive cells in precancerous tubules. Invasive tumor cells lacked both Fas and FasL expression.
Conclusions:
- The differential expression of FasL in normal versus precancerous/tumor tubules may influence immune responses.
- Reduced FasL in tumor areas could contribute to immune evasion by seminomas.
- Findings support the concept of testicular immune privilege and its potential disruption in tumorigenesis.